Goldman Sachs Maintains St. Jude Medical Neutral, $38 PT

Goldman Sachs maintained its St. Jude Medical

Neutral rating and $38 price target in a research report published today. In the report, Goldman Sachs states, "Since the company introduced late stage pipeline details (February 2011), there have been two clinical failures (US Deep Brain Stimulation trial missing primary end-point and negative CardioMEMS panel). That said, new products could be a source of upside." Shares of St. Jude Medical closed today at $40.30, up 4.51% from Tuesday's market close.